FdaApplication
NDA 201635
Identifiers
- fda_app_no: NDA201635
Properties
| Property | Value |
|---|---|
| applicant_name | SUPERNUS PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2013-08-16 |
Revenue by product
TROKENDI XR
| Period | Revenue |
|---|---|
| Q2 2026 | $8.4M |
| Q1 2026 | $9.5M |
| Q4 2025 | $8.4M |
| Q3 2025 | $10.0M |
| Q2 2025 | $11.2M |
| Q1 2025 | $12.8M |
| Q4 2024 | $14.8M |
| Q3 2024 | $15.3M |
| Q2 2024 | $17.1M |
| Q1 2024 | $16.0M |
| Q4 2023 | $19.6M |
| Q3 2023 | $20.6M |
| Q2 2023 | $19.3M |
| Q1 2023 | $34.8M |
| Q4 2022 | $57.2M |
| Q3 2022 | $69.6M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TROKENDI XR | TOPIRAMATE | 200MG | CAPSULE, EXTENDED RELEASE;ORAL |
| TROKENDI XR | TOPIRAMATE | 100MG | CAPSULE, EXTENDED RELEASE;ORAL |
| TROKENDI XR | TOPIRAMATE | 25MG | CAPSULE, EXTENDED RELEASE;ORAL |
| TROKENDI XR | TOPIRAMATE | 50MG | CAPSULE, EXTENDED RELEASE;ORAL |
4 products